Tarun Kanti Naskar

Analytical Model for the Assessment of Efficiency of Stem Cell Transplantation with Suicidal Gene Construct for the Treatment of Leukemia

Hematopoietic stem cell transplantation is now being the emergent methodology for leukemia treatment. Due to HLA mis-match, there is chance of transplantation related mortality. However, with the increase in HLA mis-match between donor cells and recipient, there is more chance of complete removal of leukemic cells in host (patient). To tackle this, recently stem cells transplantation with suicidal tk-gene construct is being suggested. Due to unavailability of suitable analytical methods this option has limited applications in clinical cases. Present work provides an analytical platform to test the efficacy of this therapeutic procedure.

Optimal Choice Between Chemotherapy and Immunotherapy for Leukemia Treatment Depends on Individual Patients’ Patho-physiological State

Chemotherapy is the firsthand choice of any cancer therapy including leukemia. However, immunosuppression is commonly seen in leukemic patients. So for the management of leukemia, cytokine-based immunotherapy is also suggested as either a combination therapy along with the conventional chemotherapy or alone. However, therapy is applied on individual patients on the basis of evidence-based medicine, i.e., population-based statistical analysis and/or on the basis of clinicians’ personal experience. Here, we propose an analytical rationality for therapeutic selection among these two options. Our simulation runs suggest that choice would be based on individual patients’ patho-physiological state like immunity profile or another hematological status. Simulation runs also suggest that in some cases chemotherapy may bring detrimental effect and direct immunotherapy would be beneficial for long-term successful therapeutic outcome. Further, this model helps in the optimization of cytokine-based immunotherapy protocol.

An Analytical Approach for the Determination of Chemotherapeutic Drug Application Trade-Offs in Leukemia

For the treatment of different leukemia different chemotherapies are available. However the success rate of any particular drug scheduling may vary with leukemic condition. In general, low dose of chemotherapy is suggested for chronic leukemia, whereas application of high dose (myeloablative) chemotherapy is applied for acute and vigorous type of leukemia. In present work we have shown that chronic type of leukemia is controlled; however, for controlling vigorously growing leukemia is a challenge due to chemotherapeutic toxicity to the normal cells of the hematopoietic system. Hence for its management, we developed a control analysis model. This model may help to design an optimal chemotherapeutic schedule so that the controlling of the vigorously growing leukemic growth can be possible in one hand with the sustenance of the normal non-leukemic cell population on the other hand. This work shows that for long-term chemotherapeutic success in individual leukemic patients demands a judicious choice of drug dosing strategy that may determine the trade-off between leukemic growth and restoration time of normal cell population of the hematopoietic system.